Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Schizophrenia Age: Adult |
Dose: Oral – Days 1-4: 1 mg Frequency: once daily Note: Day 8 titration based on clinical response and tolerability. Target dose: 2-4 mg once daily; not to exceed 4 mg/day. Periodically reassess to determine continued need. |
|
Indication: Major depressive disorder Age: Adult Condition: Adjunctive therapy to antidepressants |
Dose: Oral – 0.5 mg or 1 mg Frequency: once daily Note: Initial dose. Titrate according to clinical response and tolerability in weekly intervals to 1 mg/day and then up to 2 mg/day; not to exceed 3 mg/day. Periodically reassess to determine continued need. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Schizophrenia Age: 13 to 17 years |
Dose: Oral – 0.5 mg Frequency: once daily Duration: Days 1 to 4 Note: Max Dose: 4 mg once daily |
|
Indication: Schizophrenia Age: 13 to 17 years |
Dose: Oral – 1 mg Frequency: once daily Duration: Days 5 to 7 Note: Max Dose: 4 mg once daily |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Major Depressive Disorder Condition: Renal impairment Moderate, severe, or ESRD (Creatinine Clearance less than 60 mL/min) |
Dose: Not to exceed 2 mg/day Note: Maximum Daily Dose: Not to exceed 2 mg/day |
|
Indication: Schizophrenia Condition: Renal impairment Moderate, severe, or ESRD (Creatinine Clearance less than 60 mL/min) |
Dose: Not to exceed 3 mg/day Note: Maximum Daily Dose: Not to exceed 3 mg/day |
Administration
- Can be taken with or without food
- Take at regular intervals
Side Effect
- Akathisia (4-14%)
- Headache (4-9%)
- Weight increased (3-8%)
- Nasopharyngitis (1-7%)
- Extrapyramidal symptoms, excluding akathisia (5-6%)
- Somnolence (4-6%)
- Dyspepsia (2-6%)
- Constipation (1-6%)
- Tremor (2-5%)
- Fatigue/sedation (2-5%)
- Dizziness (1-5%)
- Increased CPK blood levels (2-4%)
- Decreased cortisol levels (2-4%)
- Anxiety (2-4%)
- Restlessness (2-4%)
- Increased appetite (2-3%)
- Diarrhea (1-3%)
- Dystonia
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
No interactions listed
|
-
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Hypersensitivity reactions
|
Can cause rash, facial swelling, urticaria
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store Brexpiprazole tablets at 20°C to 25°C; excursions permitted to 15°C to 30°C
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.